Inhibikase Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.617; its P/E ratio is -0.47; Inhibikase Therapeutics is scheduled to report earnings on May 13, 2024, and the estimated EPS forecast is $-0.79. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22
Income Statement	-
Total Revenue	$ 116.41K	$ 64.52K	$ 63.57K	$ 0.00	$ 0.00
Gross Profit	$ 116.41K	$ 64.52K	$ 63.57K	-	-
EBIT	$ -6.37M	$ -4.65M	$ -4.26M	$ -4.49M	$ -4.64M
EBITDA	$ -6.21M	$ -4.65M	$ -4.25M	$ -4.49M	$ -4.64M
Net Income Common Stockholders	$ -5.95M	$ -4.42M	$ -4.20M	$ -4.49M	$ -4.64M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 20.94M	$ 25.72M	$ 23.05M	$ 26.53M	$ 32.21M
Total Assets	$ 22.35M	$ 27.93M	$ 24.94M	$ 28.58M	$ 33.99M
Total Debt	$ 297.94K	$ 325.01K	$ 351.29K	$ 374.07K	$ 0.00
Net Debt	$ -20.64M	$ -25.39M	$ -22.70M	$ -26.16M	$ -32.21M
Total Liabilities	$ 2.88M	$ 2.84M	$ 3.90M	$ 3.45M	$ 4.49M
Stockholders Equity	$ 19.46M	$ 25.32M	$ 21.04M	$ 25.14M	$ 29.50M
Cash Flow	-
Free Cash Flow	$ -4.58M	$ -5.97M	$ -3.56M	$ -5.70M	$ -4.40M
Operating Cash Flow	$ -4.57M	$ -5.97M	$ -3.56M	$ -5.50M	$ -4.36M
Investing Cash Flow	$ 2.55M	$ -5.84M	$ 4.96M	$ -20.93M	-
Financing Cash Flow	$ -35.99K	$ 8.58M	-	$ 0.00	$ 0.00

Currency in USD

Inhibikase Therapeutics Earnings and Revenue History

Income Statement >

Inhibikase Therapeutics Debt to Assets

Balance Sheet >

Inhibikase Therapeutics Cash Flow

Cash Flow >

Inhibikase Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing